Hacettepe University Cancer Institute, Ankara, Turkey.
Faculty of Medicine, Department of Infectious Disease, Hacettepe University, Ankara, Turkey.
Int J Cancer. 2023 Feb 15;152(4):679-685. doi: 10.1002/ijc.34280. Epub 2022 Sep 23.
We aimed to evaluate the seroconversion rates after two doses of inactive COVID-19 vaccine (CoronaVac) and the benefit of a third dose mRNA vaccine booster in patients with cancer receiving active treatment. Patients with solid tumors receiving active treatment (n = 101) and patients with no-cancer (n = 48) as the control group were included in the study. All the patients and controls had received two doses of CoronaVac and a third booster dose of the mRNA vaccine (Bnt162b2). Anti-SARS-CoV-2 Spike Receptor Binding Domain IgG antibody levels after the second and third dose were measured with quantitative ELISA. The median age of the patients was 66 (IQR 60-71). 79% of the patients were receiving chemotherapy, and 21% were receiving immunotherapy at the time of vaccination. Antibody levels measured after two doses of CoronaVac were significantly lower in patients with cancer than in the control group (median 0 μg/ml [IQR 0-1.17 μg/ml] vs median 0.91 μg/ml [IQR 0-2.24 μg/ml], respectively, P = .002). Seropositivity rates were 46.5% in patients with cancer and 72.9% in the control group (P = .002). Antibody measurement was performed in 26 patients after the third dose. Seroconversion rate increased from 46.5% to 88.5% (P < .001), and the antibody titers significantly increased with the third-dose booster (median 0 μg/ml [IQR 0-1.17 μg/ml] after two doses vs 12.6 μg/ml [IQR 1.8-69.1 μg/ml] after third booster dose, P < .001). Immunogenicity of CoronaVac is low in patients with cancer receiving active treatment, and administering a third dose of an mRNA vaccine is effective in terms of improving seroconversion rates.
我们旨在评估两剂灭活 COVID-19 疫苗（科兴）接种后的血清转化率，以及在接受积极治疗的癌症患者中接种第三剂 mRNA 疫苗加强针的获益。该研究纳入了 101 例接受积极治疗的实体瘤患者（n=101）和 48 例无癌症的患者（n=48）作为对照组。所有患者和对照组均已接种两剂科兴疫苗，并接种了第三剂 mRNA 疫苗（Bnt162b2）。用定量 ELISA 法检测第二剂和第三剂后抗 SARS-CoV-2 刺突受体结合域 IgG 抗体水平。患者的中位年龄为 66 岁（IQR 60-71）。79%的患者在接种时正在接受化疗，21%的患者正在接受免疫治疗。与对照组相比，癌症患者接种两剂科兴疫苗后的抗体水平明显较低（中位数 0μg/ml[IQR 0-1.17μg/ml]与中位数 0.91μg/ml[IQR 0-2.24μg/ml]，P=0.002）。癌症患者的血清阳性率为 46.5%，对照组为 72.9%（P=0.002）。在 26 名患者中进行了第三次剂量的抗体测量。血清转化率从 46.5%增加到 88.5%（P<0.001），并且第三次剂量加强针后抗体滴度显著增加（两剂量后中位数 0μg/ml[IQR 0-1.17μg/ml]与第三剂量后中位数 12.6μg/ml[IQR 1.8-69.1μg/ml]，P<0.001）。在接受积极治疗的癌症患者中，科兴疫苗的免疫原性较低，接种第三剂 mRNA 疫苗可有效提高血清转化率。
